Liquid Biopsy Analyst at CIOC 2027

A Liquid Biopsy Analyst is a critical specialist in modern cancer diagnostics, focused on analyzing non-invasive samples—primarily blood—to detect and monitor cancer-related biomarkers. By examining circulating tumor DNA (ctDNA), RNA fragments, exosomes, and circulating tumor cells (CTCs), these analysts help uncover genetic mutations, gene fusions, and other molecular alterations linked to tumor growth and drug resistance. Utilizing advanced technologies such as digital PCR, next-generation sequencing (NGS), and high-throughput data analysis, Liquid Biopsy Analysts enable real-time insights into tumor dynamics without the need for traditional tissue biopsies. Their expertise allows for earlier cancer detection, therapy monitoring, and identification of emerging resistance, ultimately improving patient outcomes.

Liquid Biopsy Analysts play a key role in the development and validation of liquid biopsy assays, working closely with molecular pathologists, oncologists, and bioinformaticians. They interpret complex molecular data, contribute to personalized treatment planning, and support clinical trials focused on precision oncology. Their attention to quality control, assay accuracy, and emerging molecular techniques ensures that diagnostic results are both reliable and clinically actionable. As liquid biopsy continues to evolve as a transformative tool in oncology, the Liquid Biopsy Analyst remains at the forefront of innovation—bridging cutting-edge science with real-world application in the fight against cancer.